Allschwil, Switzerland, January 5, 2024

Link:
Basilea provides portfolio status update

CEO to provide update on allosteric modulator pipeline clinical and preclinical development

See the article here:
Addex to Present at Biotech Showcase™ 2024

VALNEVA

See the article here:
VALNEVA - Declaration of shares and voting rights: December 31, 2023

Liège, Belgium – December, 26 2023 – 6PM CET – Regulated information – Inside Information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces positive results from a pivotal clinical study for its proprietary Valacyclovir Oral Suspension. It allows for further preparation of a NDA1 for submission to the FDA expected in 2024.

Read more from the original source:
Hyloris Announces Positive Clinical Study Results for Valacyclovir Oral Suspension (HY-029)

PETALUMA, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has contracted with MEDsan, Inc. (“MEDsan” to provide diagnostic testing services for its Institutional Review Board (IRB) to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration, which was previously announced on October 30, 2023 (see the link.)

Read more here:
RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a...

– Innovative design enables five-minute pegfilgrastim delivery time –

Go here to see the original:
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

ORION CORPORATION PRESS RELEASE 27 DECEMBER 2023 at 11:00 EET                      NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208

Continue reading here:
NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208

First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical programs built around Capeserod and Adrulipase First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical programs built around Capeserod and Adrulipase

Read more:
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

MELBOURNE, Australia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that it expects to receive the remaining US$35 million committed funds under the Development Funding Agreement (DFA) with Carlyle and Abingworth, and has entered into binding documentation with a new co-investor under an Amended DFA to secure an additional US$50 million in funding.

Excerpt from:
Opthea to Receive US$35M Commitment and Additional US$50M Funding

BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. PT in San Francisco.

Read more from the original source:
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023. The Company’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis beginning on December 29, 2023, under the Company’s existing trading symbol “AVTX”.

Original post:
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

SAN CARLOS, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC).

See the article here:
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM)

Read this article:
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or...

In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNF?, reductions in tissue TNF? mRNA and improvement in disease activity scores

View original post here:
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small...

NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA clearance by Health Canada for a phase 1/2a clinical trial in moderate Alzheimer’s Disease patients

Read the original post:
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease

Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costs Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costs

Read more:
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed -

Go here to see the original:
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo®...

This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives.

Visit link:
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

IRVINE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to provide this end-of-the year message to shareholders.

The rest is here:
Nymox December 27 Message to Shareholders

BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 881,337 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $5.50 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $4.8 million, before deducting financial advisory fees. The reduction in the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules.

See the article here:
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced